ECSP11011313A - Compuestos y usos de los mismos - Google Patents

Compuestos y usos de los mismos

Info

Publication number
ECSP11011313A
ECSP11011313A EC2011011313A ECSP11011313A ECSP11011313A EC SP11011313 A ECSP11011313 A EC SP11011313A EC 2011011313 A EC2011011313 A EC 2011011313A EC SP11011313 A ECSP11011313 A EC SP11011313A EC SP11011313 A ECSP11011313 A EC SP11011313A
Authority
EC
Ecuador
Prior art keywords
pyrrolo
difluoro
pyridine
carbonyl
phenyl
Prior art date
Application number
EC2011011313A
Other languages
English (en)
Inventor
Prabha N Ibrahim
Wayne Spevak
Hongyao Zhu
Hanna Cho
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of ECSP11011313A publication Critical patent/ECSP11011313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen los compuestos ácido propano-1-sulfónico de {2,4-difluoro-3-[5-(2-metoxi-pirimidin-5-il)-1H-pirrolo[2,3-b]piridina-3-carbonil]-fenil}-amida, ácido propano-1-sulfónico de [3-(5-ciano-1H-pirrolo[2,3-b]piridina-3-carbonil)-2,4-difluoro-fenil]-amida, ácido propano-1-sulfónico de [3-(5-ciano-1H-pirrolo[2,3-b]piridina-3-carbonil)-2-fluoro-fenil]-amida, N-[3-(5-ciano-1H-pirrolo[2,3-b]piridina-3-carbonil)-2,4-difluoro-fenil]-2,5-difluoro-bencenosulfonamida, N-[3-(5-ciano-1H-pirrolo[2,3-b]piridina-3-carbonil)-2,4-difluoro-fenil]-3-fluoro-bencenosulfonamida, ácido pirrolidina-1-sulfónico de [3-(5-ciano-1H-pirrolo[2,3-b]piridina-3-carbonil)-2,4-difluoro-fenil]-amida, ácido N,N-dimetilamino-sulfónico de [3-(5-ciano-1H-pirrolo[2,3-b]piridina-3-carbonil)-2,4-difluoro-fenil]-amida, y sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos, formas de los mismos y usos de los mismos. En ciertos aspectos y realizaciones, los compuestos descritos o sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos y formas de los mismos son activos sobre por lo menos una proteína quinasa Raf. También se describen unos métodos de uso de los mismos para tratar enfermedades y condiciones, incluyendo enfermedades y condiciones asociadas con la actividad de las proteínas quinasas Raf, incluyendo melanoma, glioma, cáncer colorrectal, cáncer de tiroides, cáncer de pulmón, cáncer ovárico, cáncer de próstata y cáncer del tracto biliar.
EC2011011313A 2009-03-11 2011-08-09 Compuestos y usos de los mismos ECSP11011313A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15939009P 2009-03-11 2009-03-11
US15939209P 2009-03-11 2009-03-11
US15940009P 2009-03-11 2009-03-11
US15939609P 2009-03-11 2009-03-11
US15940209P 2009-03-11 2009-03-11
US15940609P 2009-03-11 2009-03-11
US15939509P 2009-03-11 2009-03-11

Publications (1)

Publication Number Publication Date
ECSP11011313A true ECSP11011313A (es) 2011-10-31

Family

ID=42199540

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011313A ECSP11011313A (es) 2009-03-11 2011-08-09 Compuestos y usos de los mismos

Country Status (23)

Country Link
US (1) US8901301B2 (es)
EP (1) EP2406259A1 (es)
JP (1) JP2012520307A (es)
KR (1) KR101663339B1 (es)
CN (1) CN102421776A (es)
AR (1) AR075812A1 (es)
AU (1) AU2010224245B2 (es)
BR (1) BRPI1011515A2 (es)
CA (1) CA2755045A1 (es)
CO (1) CO6620074A2 (es)
CR (1) CR20110476A (es)
EC (1) ECSP11011313A (es)
MA (1) MA33181B1 (es)
MX (1) MX2011009489A (es)
MY (1) MY161861A (es)
NI (1) NI201100168A (es)
NO (1) NO20111241A1 (es)
PE (1) PE20120184A1 (es)
RU (1) RU2011141123A (es)
SG (2) SG10201402977WA (es)
TW (1) TW201036973A (es)
WO (1) WO2010104945A1 (es)
ZA (1) ZA201106599B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
BR112012015745A2 (pt) * 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
WO2012075327A1 (en) 2010-12-02 2012-06-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for treating a tumor using an antibody that specifically binds grp94
US9624213B2 (en) * 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2701694A4 (en) 2011-04-28 2014-10-08 Univ Duke METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
JP6113151B2 (ja) 2011-05-17 2017-04-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症
US9988687B2 (en) * 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
EP2892534B8 (en) 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014081760A1 (en) 2012-11-20 2014-05-30 Duke University Methods of treating hemoglobinopathies
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
DK2970265T3 (en) 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
CA2963091A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6530826B2 (ja) 2015-05-06 2019-06-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを修飾する１ｈ−ピロロ［２，３−ｂ］ピリジン誘導体の合成
LT3292123T (lt) 2015-05-06 2020-12-28 Plexxikon Inc. Junginio, moduliuojančio kinazes, kietos formos
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2913048T3 (es) 2015-09-21 2022-05-31 Opna Immuno Oncology Sa Compuestos heterocíclicos y usos de estos
MX2018006856A (es) 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
EP3558991A2 (en) 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
JP2020511467A (ja) 2017-03-20 2020-04-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ブロモドメインを阻害する４−（１−（１，１−ジ（ピリジン−２−イル）エチル）−６−（３，５−ジメチルイソオキサゾール−４−イル）−１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−イル）安息香酸の結晶形
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
AU2018307910B2 (en) 2017-07-25 2024-07-25 Daiichi Sankyo Company, Limited Formulations of a compound modulating kinases
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
AU2018354423B2 (en) 2017-10-27 2024-11-07 Plexxikon Inc. Formulations of a compound modulating kinases
NZ766594A (en) 2018-01-31 2025-12-19 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
GB201809460D0 (en) * 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
EP3810139A1 (en) 2018-06-21 2021-04-28 HepaRegeniX GmbH Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL279641B2 (en) 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202110714VA (en) 2019-04-09 2021-10-28 Plexxikon Inc Condensed azines for ep300 or cbp modulation and indications therefor
US12509444B2 (en) 2019-12-06 2025-12-30 Plexxikon Inc. Compounds and methods for CD73 modulation and indications therefor
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
US11807626B2 (en) 2020-04-23 2023-11-07 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
WO2021222442A1 (en) 2020-04-29 2021-11-04 Plexxikon Inc. Synthesis of heterocyclic compounds
JP2023530030A (ja) 2020-06-19 2023-07-12 シーフォー セラピューティクス， インコーポレイテッド Ｂｒａｆ分解剤
TW202227068A (zh) 2020-08-21 2022-07-16 美商普雷辛肯公司 組合藥物療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa

Also Published As

Publication number Publication date
KR101663339B1 (ko) 2016-10-06
KR20110125670A (ko) 2011-11-21
RU2011141123A (ru) 2013-04-20
ZA201106599B (en) 2014-02-26
CN102421776A (zh) 2012-04-18
EP2406259A1 (en) 2012-01-18
NO20111241A1 (no) 2011-09-28
SG10201402977WA (en) 2014-09-26
CA2755045A1 (en) 2010-09-16
JP2012520307A (ja) 2012-09-06
MX2011009489A (es) 2011-10-11
PE20120184A1 (es) 2012-03-28
CR20110476A (es) 2012-01-04
AR075812A1 (es) 2011-04-27
MY161861A (en) 2017-05-15
CO6620074A2 (es) 2013-02-15
BRPI1011515A2 (pt) 2016-03-29
AU2010224245A1 (en) 2011-09-29
WO2010104945A1 (en) 2010-09-16
US8901301B2 (en) 2014-12-02
US20100286178A1 (en) 2010-11-11
SG174257A1 (en) 2011-10-28
MA33181B1 (fr) 2012-04-02
TW201036973A (en) 2010-10-16
NI201100168A (es) 2012-01-11
AU2010224245B2 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
ECSP11011313A (es) Compuestos y usos de los mismos
NI201100189A (es) Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos
AR076105A1 (es) Derivados pirrol[2,3-b]piridina para inhibir la raf quinasa
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
CO6781467A2 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
EA201001699A1 (ru) Сложные эфиры и тиоэфиры тиазол-4-карбоновой кислоты в качестве средств защиты растений
MX2010006436A (es) Derivados peptidos mimeticos de eritropoyetina y sus sales farmaceuticas, su preparacion y usos.
FR2918061B1 (fr) Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
GT200500132A (es) Formulaciones acuosas concentradas para la proteccion de las plantas
UY31829A (es) Compuestos y métodos para modulación de cinasas, e indicaciones para ello
MA33023B1 (fr) Formulation d'anticorps
EA200901597A1 (ru) Гербицидно активные бициклические 1,3-дионы
ATE387450T1 (de) Meso-substituierte porphyrine
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
ATE553096T1 (de) Pyridazinderivate und ihre verwendung als therapeutische wirkstoffe
BR112013015498A2 (pt) formulação localizada tópica, uso da formulação, e, método para tratamento ou profilaxia de infestação de parasita de um animal
NI201300081A (es) Uso de 3 - ( 5 - amino - 2 - metil - 4 - oxoquinazolin - 3(4h) - il) piperidin - 2 - 6 -diona en el tratamiento de enfermedades relacionadas con el sistema inmunitario e inflamatorias.
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
TR200806298A2 (tr) Farmasötik formülasyon
UY33643A (es) ?Conjugado cristalino de naloxol-PEG?.
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
ITRM20080214A1 (it) Derivati dell'acido butirrico somministrabili per via orale, formulazioni che li contengono e loro uso clinico.
FR2925902B1 (fr) DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью